Shire expands early-stage rare disease work with Ethris and arGEN-X
This article was originally published in Scrip
Shire has expanded its early-stage collaboration work in the area of rare diseases through extended partnerships with European firms Ethris and arGEN-X.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.